150 related articles for article (PubMed ID: 21897414)
1. Role of 5-aminosalicylate in preventing colorectal cancer.
Riyaz S; Hamlin J; Everett S
Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414
[No Abstract] [Full Text] [Related]
2. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.
Levine JS; Burakoff R
Inflamm Bowel Dis; 2007 Oct; 13(10):1293-8. PubMed ID: 17567870
[TBL] [Abstract][Full Text] [Related]
3. [5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?].
Desreumaux P; Romano O
Gastroenterol Clin Biol; 2004 May; 28(5):509. PubMed ID: 15243337
[No Abstract] [Full Text] [Related]
4. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
5. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
Munkholm P; Loftus EV; Reinacher-Schick A; Kornbluth A; Mittmann U; Esendal B
Digestion; 2006; 73(1):11-9. PubMed ID: 16410688
[TBL] [Abstract][Full Text] [Related]
6. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
Tang J; Sharif O; Pai C; Silverman AL
Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
[TBL] [Abstract][Full Text] [Related]
7. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
8. [Inflammatory bowel disease and colorectal cancer].
Hagymási K; Tulassay Z
Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
Rubin DT; Cruz-Correa MR; Gasche C; Jass JR; Lichtenstein GR; Montgomery EA; Riddell RH; Rutter MD; Ullman TA; Velayos FS; Itzkowitz S;
Inflamm Bowel Dis; 2008 Feb; 14(2):265-74. PubMed ID: 17932965
[TBL] [Abstract][Full Text] [Related]
10. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.
Bernstein CN; Eaden J; Steinhart AH; Munkholm P; Gordon PH
Inflamm Bowel Dis; 2002 Sep; 8(5):356-61. PubMed ID: 12479651
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
van Staa TP; Card T; Logan RF; Leufkens HG
Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
13. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
Chapman CG; Rubin DT
Gastrointest Endosc Clin N Am; 2014 Jul; 24(3):353-65. PubMed ID: 24975527
[TBL] [Abstract][Full Text] [Related]
14. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
Giannini EG; Kane SV; Testa R; Savarino V
Dig Liver Dis; 2005 Oct; 37(10):723-31. PubMed ID: 16023905
[TBL] [Abstract][Full Text] [Related]
15. 5-aminosalicylate is not protective from neoplasia in ulcerative colitis.
Bessissow T; Bisschops R; Ferrante M; Baert F; Van Assche G; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):1015. PubMed ID: 23735927
[No Abstract] [Full Text] [Related]
16. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
OʼConnor A; Packey CD; Akbari M; Moss AC
Inflamm Bowel Dis; 2015 Nov; 21(11):2562-9. PubMed ID: 26296062
[TBL] [Abstract][Full Text] [Related]
17. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
[TBL] [Abstract][Full Text] [Related]
18. Thorax as an extraintestinal target for inflammatory bowel disease.
Akpınar EE; Gülhan M; Değertekin H; Ataoğlu Ö
Tuberk Toraks; 2011; 59(3):312-5. PubMed ID: 22087529
[No Abstract] [Full Text] [Related]
19. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
Ryan BM; Russel MG; Langholz E; Stockbrugger RW
Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319
[TBL] [Abstract][Full Text] [Related]
20. [5-aminosalicylic acid and cancer prophylaxis?].
Thomsen OO
Ugeskr Laeger; 2006 May; 168(21):2047. PubMed ID: 16768920
[No Abstract] [Full Text] [Related]
[Next] [New Search]
